Immunomodulator plus cancer therapy for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how well a type of drug called an immunomodulator, given together with other cancer treatments, works for people with colorectal cancer. It aims to see if combining these therapies can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years old or older.
- You have been diagnosed with colorectal cancer.
- You started your cancer treatment between January 1, 2020, and April 30, 2024.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of a GSL synthesis inhibitor, an immunotherapy drug, and/or regorafenib in people with a specific type of colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if this new approach can help shrink or control the cancer.
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.